Cravit Contraindications

Patients with a history of hypersensitivity to levofloxacin, ofloxacin or to any excipients of Cravit.
Patients with epilepsy and those with history of tendon disorder related to fluoroquinolone administration.
Use in Pregnancy: Levofloxacin caused no impairment of fertility or reproductive performance in rats at oral doses as high as 360 mg/kg/day. It was not teratogenic in rats at oral doses as high as 810 mg/kg/day or at IV dose up to 160 mg/kg/day. No teratogenicity was observed when rabbits were dosed orally as high as 50 mg/kg/day.
In the absence of human data and due to the experimental risk of damage by fluoroquinolones to the weight-bearing cartilage of the growing organism, Cravit must not be used in pregnant women or women suspected of being pregnant.
Use in Lactation: In the absence of human data and due to the experimental risk of damage by fluoroquinolones to the weight-bearing cartilage of the growing organism, Cravit must not be used in breastfeeding women.
Use in Children: Safety and effectiveness in pediatric patients and adolescents <16 years have not been established. Quinolones, including levofloxacin, cause arthropathy and osteochondrosis in juvenile animals of several species.